News

We would like to invite you to a lectures of prof. Uta Dahmen and prof. Ajay Goel, that that will be featured on 10th July 2019 in this year's Summer School of Experimental Surgery. The lectures are open, so non-SSES audience is welcome too!

Looking forward to seeing you there!

Read more... Last modified on
  • Project number: LTC19015
  • Applicant organization: Charles University, Faculty of Medicine in Pilsen
  • Principal Investigator: doc. RNDr. Pavel Souček, CSc.
  • Duration of the project: 1. 6. 2019 – 30. 9. 2022
  • Funded by The Ministry of Education, Youth and Sports – Program INTER-EXCELLENCE, INTER-COST
Read more... Last modified on

In July 2019 the team headed by Dr. Pavel Vodicka (Laboratory of Tumor Treatment and Tissue Regeneration at Biomedical Center, Pilsen) succeeded to publish original manuscript: „Relationship of telomere length in colorectal cancer patients with cancer phenotype and patient prognosis” in British Journal of Cancer.

Read more... Last modified on

Lectures from invited speakers from foreign countries are traditionally a part of the Summer School of Experimental Surgery, which was held for the 6th time this year by our faculty.

Read more... Last modified on

Biomedical Center of Faculty of Medicine in Pilsen in collaboration with University of West Bohemia invites you to INTERNATIONAL SEMINAR: The power of data analysis: from lab through analysis to databases 7. 10. 2019 from 3 p.m. Room no. 4.201 (Practice room I), Institute of Pathological Physiology, UNIMEC, 1st floor.

Read more... Last modified on

Students interested in molecular biology, cancer genetics and bioinformatics with background in biology or informatics are welcomed to apply for this position.

Further information by Pavel Dvorak, Ph.D., Charles University, Faculty of Medicine in Pilsen, Department of Biology, Alej Svobody 76, 323 00 Pilsen, Czech Republic, Tel.: +420 377 593 263, Email: This email address is being protected from spambots. You need JavaScript enabled to view it..

Read more... Last modified on
Laboratoř buněčné regenerativní medicíny zve na přednášku doc. Mgr. Tomáše Doležala, Ph.D. (vedoucí Katedry molekulární biologie a genetiky, vedoucí Laboratoře molekulární integrativní fyziologie drozofily, Přírodovědecká fakulta Jihočeské univerzity v Českých Budějovicich) Fruit fly model for examining selfish immunity dne 25. 9. 2019 ve 14:00 v seminární místnosti Biomedicínského centra (SO 01.2.21).
Read more... Last modified on

The Chaperon ERA Chairs project has been ceremonially initiated by the Chaperon Kick-off Meeting held on September 26, 2019, at the Biomedical Center, Faculty of Medicine in Pilsen, Charles University. The project, officially titled “CHAPERON – ERA Chair Position for Excellent Research in Oncology“, will allow the Faculty to find and hire a world-class cancer researcher and research manager.

Read more... Last modified on

From November 4 to November 8 2019, the Biomedical Center of our Faculty hosted esteemed international visitors. Following up upon a long-term collaboration including one international grant funded from the Erasmus+ program, we had the honor to welcome two professors from Rome. Prof. Alberto Paoluzzi from Italian Roma Tre University and Prof. Antonio DiCarlo from CECAM-IT-SIMUL Node are specialized in the field of computational modeling and object representation.

Read more... Last modified on

The second annual meeting of our research project "Centrum of Clinical and Experimental Liver Surgery" (UNCE/MED/006) was held on Saturday, November 23, 2019. The members of our team as well as our colleagues from collaborating labs presented their results. We've also arranged the details on future collaboration. The meeting progressed in a relaxed and friendly way, free from the tight schedules of busy work days.

Read more... Last modified on

Each year, the international biotechnology enterprise Roche distributes the Czech DIGI@MED Awards to authors of innovative digital and mobile solutions in medicine and healthcare process optimization. The goal of the award is to support young innovators in their bold endeavours in utilising digital technologies for better clinical care, health and well-being. The contenders were evaluated by a panel of renowned healthcare and IT professionals, who considered not only the benefits that the solutions offer to clinicians and pharmacists, but mainly their positive effects for patients.

Read more... Last modified on

The Tumor Therapy and Tissue Regeneration team of the Biomedical Center of the Faculty of Medicine, Charles University in Pilsen has achieved great success by publishing a comprehensive review summarizing the treatment options for colorectal cancer and the mechanisms of action of 5-Fluorouracil at the molecular level, including anabolic and catabolic pathways in Pharmacology & Therapeutics journal.

Read more... Last modified on

The Laboratory of Pharmacogenomics team of the Biomedical Center of the Faculty of Meidicine, Charles University in Pilsen has achieved great success by contribution in publishing of a comprehensive review summarizing new technologies and methods in the research of cancer multidrug-resistance (MDR) phenomen in Drug Resistance Updates.

Read more... Last modified on

In November 2019, the paper „Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients“ was published in Cancers (Q1, IF2019: 6.162). This is an extensive retrospective study involving a total of 514 patients with metastatic colorectal cancer who were treated between 2005 and 2019 at the Department of Oncology and Radiotherapy, Faculty of Medicine and University Hospital in Pilsen, Charles University. The work, led by Assoc. Prof. Ondřej Fiala, M.D., Ph.D., is based on the systematic cooperation of the Department of Oncology and Radiotherapy, the Department of Surgery and the Faculty of Medicine in Pilsen, Charles University. This collaboration is carried out under the auspices of the Laboratory of Tumor Treatment and Tissue Regeneration of the Medical Faculty’s Biomedical Center, which has long been involved in various clinical and experimental aspects of colorectal cancer and primary liver tumours.

Beta-adrenergic signalling plays an essential role in several processes that are important for the development and progression of various cancers. These processes include angiogenesis. The effect of the use of beta-blockers on the prognosis of cancer patients treated with anti-angiogenic agents is unclear and has been scarcely studied clinically. The aim of this study was to evaluate the association between the use of beta-blockers and the effect of treatment with a combination of chemotherapy and bevacizumab (a monoclonal antibody against vascular endothelial growth factor), which blocks angiogenesis. The association between progression-free survival (PFS) and overall survival (OS) with the use of beta-blockers and other common antihypertensive agents was evaluated. Of the commonly used antihypertensive agents, only beta-blockers had a significant impact on survival. The medians of PFS and OS in patients using beta-blockers prolonged to 11.4 and 26.8 months compared to the baseline values of 8.3 and 21.0 months in patients not using beta-blockers (p = 0.006 and p = 0.009, respectively). In the Cox multivariate model, the use of beta-blockers was a significant factor predicting both PFS (HR = 0.763, p = 0.021) and OS (HR = 0.730, p = 0.020). The results of this study show a significant association between the use of beta-blockers and the effect of treatment based on a combination of chemotherapy and bevacizumab. This is the first study of this kind conducted in a clinically relevant group of patients suggesting that beta-blockers might be the preferred type of antihypertensive in patients with metastatic colorectal cancer treated with this type of targeted therapy.

“From a clinical point of view, comedication is an extremely interesting topic in cancer patients. Although the results of this study are interesting, they need to be interpreted with caution, mainly because of its non-randomized retrospective design. We will stay focused on this topic with respect to other malignancies where anti-angiogenic targeted treatment is used,” adds doc. Fiala.

www.ncbi.nlm.nih.gov/pubmed/31769417

Vaclav Liska

Read more... Last modified on

The Laboratory of Cancer treatment and Tissue Regeneration successfully published an article ‚Experimental fortification of intestinal anastomoses with nanofibrous materials in a large animal model‘ in the Scientific Reports journal (Q1, IF = 4.116). The paper sums results of the first use of nanofibrous materials from polycaprolactone for intestinal anastomotic healing support in an experiment on pigs.

Read more... Last modified on

Contact

Charles University
Faculty of Medicine in Pilsen
Biomedical Center

alej Svobody 1655/76
323 00 Plzeň – Severní Předměstí

T: +420 377 593 810
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

Login

Log in to your account or Create an account